Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 376-381

  Rahimian, Reza ^a   Fakhfouri, Gohar ^b   Daneshmand, Ali ^c   Mohammadi, Hamed ^a   Bahremand, Arash ^a   Rasouli, Mohammad Reza ^a   Mousavizadeh, Kazem ^d   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adenosine receptor; Inflammatory bowel disease; Inosine; Uric acid

Indexed keywords

5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; INOSINE; INTERLEUKIN 1BETA; MALONALDEHYDE; MYELOPEROXIDASE; OXONATE POTASSIUM; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON INJURY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SPRAGUE DAWLEY RAT; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BIOLOGICAL MARKERS; COLITIS; COLON; DIETARY SUPPLEMENTS; DRUG SYNERGISM; ENZYME INHIBITORS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INOSINE MONOPHOSPHATE; LIPID PEROXIDATION; MACROPHAGES; MALE; NEUTROPHIL INFILTRATION; OXONIC ACID; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; SEVERITY OF ILLNESS INDEX; URATE OXIDASE; URIC ACID;

EID: 78049291834     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.044     Document Type: Article

References (34)

1. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
2. Becker B.F. Towards the physiological function of uric acid. Free Radic. Biol. Med. 1993, 14:615-631.
3. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 1982, 78:206-209.
4. Buffinton G.D., Doe W.F. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic. Biol. Med. 1995, 19:911-918.
5. Cuzzocrea S., Ianaro A., Wayman N.S., Mazzon E., Pisano B., Dugo L., Serraino I., Di Paola R., Chatterjee P.K., Di Rosa M., Caputi A.P., Thiemermann C. The cyclopentenone prostaglandin 15-deoxy-delta(12, 14)- PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br. J. Pharmacol. 2003, 138:678-688.
6. Fillmann H., Kretzmann N.A., San-Miguel B., Llesuy S., Marroni N., Gonzalez-Gallego J., Tunon M.J. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology 2007, 236:217-226.
7. Hasko G., Kuhel D.G., Nemeth Z.H., Mabley J.G., Stachlewitz R.F., Virag L., Lohinai Z., Southan G.J., Salzman A.L., Szabo C. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J. Immunol. 2000, 164:1013-1019.
8. Hasko G., Sitkovsky M.V., Szabo C. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol. Sci. 2004, 25:152-157.
9. Hasko G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 2008, 7:759-770.
10. Hooper D.C., Scott G.S., Zborek A., Mikheeva T., Kean R.B., Koprowski H., Spitsin S.V. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. 2000, 14:691-698.
11. Kastenbauer S., Koedel U., Becker B.F., Pfister H.W. Experimental meningitis in the rat: protection by uric acid at human physiological blood concentrations. Eur. J. Pharmacol. 2001, 425:149-152.
12. Liaudet L., Mabley J.G., Soriano F.G., Pacher P., Marton A., Hasko G., Szabo C. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am. J. Respir. Crit. Care Med. 2001, 164:1213-1220.
13. Liaudet L., Mabley J.G., Pacher P., Virag L., Soriano F.G., Marton A., Hasko G., Deitch E.A., Szabo C. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann. Surg. 2002, 235:568-578.
14. Mabley J.G., Pacher P., Liaudet L., Soriano F.G., Hasko G., Marton A., Szabo C., Salzman A.L. Inosine reduces inflammation and improves survival in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284:G138-G144.
15. Mabley J.G., Rabinovitch A., Suarez-Pinzon W., Hasko G., Pacher P., Power R., Southan G., Salzman A., Szabo C. Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Mol. Med. 2003, 9:96-104.
16. Maunder R. Mediators of stress effects in inflammatory bowel disease: not the usual suspects. J. Psychosom. Res. 2000, 48:569-577.
17. Mazzon E., Esposito E., Crisafulli C., Riccardi L., Muia C., Di Bella P., Meli R., Cuzzocrea S. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J. Pineal Res. 2006, 41:363-373.
18. McCafferty D.M. Peroxynitrite and inflammatory bowel disease. Gut 2000, 46:436-439.
19. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803.
20. Mousavizadeh K., Dehpour A.R., Minagar A., Ghafourifar P. Uric acid: a novel treatment strategy for multiple sclerosis. Trends Pharmacol. Sci. 2003, 24:563-564. author reply 564-565.
21. Naganuma M., Wiznerowicz E.B., Lappas C.M., Linden J., Worthington M.T., Ernst P.B. Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol. 2006, 177:2765-2769.
22. Neurath M.F., Fuss I., Kelsall B., Meyer zum Buschenfelde K.H., Strober W. Effect of IL-12 and antibodies to IL-12 on established granulomatous colitis in mice. Ann. NY Acad. Sci. 1996, 795:368-370.
23. Odashima M., Bamias G., Rivera-Nieves J., Linden J., Nast C.C., Moskaluk C.A., Marini M., Sugawara K., Kozaiwa K., Otaka M., Watanabe S., Cominelli F. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005, 129:26-33.
24. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
25. Pavlick K.P., Laroux F.S., Fuseler J., Wolf R.E., Gray L., Hoffman J., Grisham M.B. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic. Biol. Med. 2002, 33:311-322.
26. Podolsky D.K. Inflammatory bowel disease. N Engl J. Med. 2002, 347:417-429.
27. Scott G.S., Spitsin S.V., Kean R.B., Mikheeva T., Koprowski H., Hooper D.C. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc. Natl Acad. Sci. USA 2002, 99:16303-16308.
28. Scott G.S., Cuzzocrea S., Genovese T., Koprowski H., Hooper D.C. Uric acid protects against secondary damage after spinal cord injury. Proc. Natl Acad. Sci. USA 2005, 102:3483-3488.
29. Starling R.D., Trappe T.A., Short K.R., Sheffield-Moore M., Jozsi A.C., Fink W.J., Costill D.L. Effect of inosine supplementation on aerobic and anaerobic cycling performance. Med. Sci. Sports Exerc. 1996, 28:1193-1198.
30. Tuzun A., Erdil A., Inal V., Aydin A., Bagci S., Yesilova Z., Sayal A., Karaeren N., Dagalp K. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin. Biochem. 2002, 35:569-572.
31. Wallace J.L., Keenan C.M., Gale D., Shoupe T.S. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 1992, 102:18-27.
32. Waring W.S. Uric acid: an important antioxidant in acute ischaemic stroke. QJM 2002, 95:691-693.
33. Ye J.H., Rajendran V.M. Adenosine: an immune modulator of inflammatory bowel diseases. World J. Gastroenterol. 2009, 15:4491-4498.
34. Yoshida N., Yoshikawa T., Yamaguchi T., Naito Y., Tanigawa T., Murase H., Kondo M. A novel water-soluble vitamin E derivative protects against experimental colitis in rats. Antioxid. Redox Signal. 1999, 1:555-562.